Marseilles, France, May 5, 2011 -- Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces today the reinforcement of its management with the appointment of Catherine Moukheibir to its Executive board, as Senior Advisor Finance.
Catherine Moukheibir, MA, MBA (from Yale University), will be in charge of the financial strategy of the Company. She has 16 years of experience in finance including 10 in the biotechnology industry. Prior to joining Innate Pharma, Mrs Moukheibir was CFO of Movetis, a Belgian biotech company (from 2008 to 2010), for which she led the IPO on Euronext Brussels and then the acquisition by Shire. Previously, she was Director Capital Markets at Zeltia (from 2001 to 2007), a Spanish biopharma and consumer chemicals group, where she led financial strategy. Before joining Zeltia, she was Executive Director Investment Banking with Salomon Smith Barney and Morgan Stanley (from 1997 to 2000).
“We are very happy to welcome Catherine Moukheibir to our team. She brings extensive experience in our sector, from both the industry and banking perspectives. She also knows very well the investor community, in Europe as well as in the United States, and we hope that she will contribute to expand Innate Pharma’s visibility through the realignment of its history and perspectives”, said Hervé Brailly, CEO of Innate Pharma.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.
The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its most advanced drug- candidate is IPH 2101, an anti-KIR monoclonal antibody potentiating NK cells activation currently in Phase II clinical trials in hematologic cancers. Two of its antibody programs in chronic inflammation are out-licensed to Novo Nordisk A/S.
Innate Pharma’s key expertise is in immunopharmacology and antibody technology. The Company has implemented in-house a large panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics and pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to a very large set of unique research tools in cellular immunology through its worldwide network of scientific collaborations.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 85 employees as at March 31, 2011.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
ISIN code
Ticker code
FR0010331421
IPH
Disclaimer: This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Innate Pharma
Laure-Hélène Mercier
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com
Alize Public Relations
Caroline Carmagnol
Phone: +33 (0)1 41 22 07 31
Mobile: +33 (0)6 64 18 99 59
caroline@alizerp.com
